title: Serum biomarkers for personalization of nanotherapeutics-based therapy in different tumor and organ microenvironments.
abstract: Enhanced permeation and retention (EPR) effect, the mechanism by which nanotherapeutics accumulate in tumors, varies in patients based on differences in the tumor and organ microenvironment. Surrogate biomarkers for the EPR effect will aid in selecting patients who will accumulate higher amounts of nanotherapeutics and show better therapeutic efficacy. Our data suggest that the differences in the vascular permeability and pegylated liposomal doxorubicin (PLD) accumulation are tumor type as well as organ-specific and significantly correlated with the relative ratio of MMP-9 to TIMP-1 in the circulation, supporting development of these molecules as biomarkers for the personalization of nanoparticle-based therapy.
authors.affiliation: Department of Nanomedicine, Houston Methodist Research Institute, 6670 Bertner Street, Houston, TX 77030, USA; Department of Cancer Biology, Cancer Metastasis Research Center, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA. Electronic address: kyokoi2@tmhs.org.
authors.forename: Kenji
authors.initials: K
authors.lastname: Yokoi
authors.affiliation: Department of Nanomedicine, Houston Methodist Research Institute, 6670 Bertner Street, Houston, TX 77030, USA.
authors.forename: Tomonori
authors.initials: T
authors.lastname: Tanei
authors.affiliation: Department of Nanomedicine, Houston Methodist Research Institute, 6670 Bertner Street, Houston, TX 77030, USA.
authors.forename: Biana
authors.initials: B
authors.lastname: Godin
authors.affiliation: Department of Nanomedicine, Houston Methodist Research Institute, 6670 Bertner Street, Houston, TX 77030, USA.
authors.forename: Anne L
authors.initials: AL
authors.lastname: van de Ven
authors.affiliation: Department of Cancer Biology, Cancer Metastasis Research Center, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA.
authors.forename: Masaki
authors.initials: M
authors.lastname: Hanibuchi
authors.affiliation: Department of Cancer Biology, Cancer Metastasis Research Center, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA.
authors.forename: Aika
authors.initials: A
authors.lastname: Matsunoki
authors.affiliation: Department of Nanomedicine, Houston Methodist Research Institute, 6670 Bertner Street, Houston, TX 77030, USA.
authors.forename: Jenolyn
authors.initials: J
authors.lastname: Alexander
authors.affiliation: Department of Nanomedicine, Houston Methodist Research Institute, 6670 Bertner Street, Houston, TX 77030, USA. Electronic address: mferrari@tmhs.org.
authors.forename: Mauro
authors.initials: M
authors.lastname: Ferrari
mesh_terms: D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage / Q000493:pharmacokinetics; D014408:Biomarkers, Tumor / Q000097:blood*; D001932:Brain Neoplasms / Q000097:blood / Q000188:drug therapy / Q000378:metabolism / Q000556:secondary; D002199:Capillary Permeability; D004317:Doxorubicin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D016503:Drug Delivery Systems; D005260:Female; D008114:Liver Neoplasms, Experimental / Q000097:blood / Q000188:drug therapy / Q000378:metabolism; D020780:Matrix Metalloproteinase 9 / Q000097:blood; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D008819:Mice, Nude; D053758:Nanoparticles / Q000008:administration & dosage / Q000378:metabolism; D009374:Neoplasms, Experimental / Q000097:blood* / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D011092:Polyethylene Glycols / Q000008:administration & dosage / Q000493:pharmacokinetics; D019715:Tissue Inhibitor of Metalloproteinase-1 / Q000097:blood; D059016:Tumor Microenvironment; D023041:Xenograft Model Antitumor Assays
chemical_list: D000903:Antibiotics, Antineoplastic; D014408:Biomarkers, Tumor; D019715:Tissue Inhibitor of Metalloproteinase-1; C506643:liposomal doxorubicin; D011092:Polyethylene Glycols; D004317:Doxorubicin; D020780:Matrix Metalloproteinase 9
keywords: Biomarker; EPR effect; Nanotherapeutics; PLD; Transport oncophysics